Product Name:

DTNA-pT504


Product Number:

ab-pn954

Price:

Regular price
$98.00
Regular price
Sale price
$98.00

Download Product PDF

Target Full Name: Dystrobrevin alpha

Target Alias: D18S892E; DRP3; DTN; DTN-1; DTN-2; DTN-3; Dystrobrevin, alpha; Dystrophin-related protein 3; LVNC1

Product Type Specific: DTNA phosphosite-specific antibody

Antibody Code: PN954

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: T504

Protein UniProt: Q9Y4J8

Protein SigNET: DTNA

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Synthetic phosphopeptide patterned after human DTNA

Antibody Immunogen Sequence: ASQP(pT)PEKAC

Antibody Immunogen Description: Corresponds to amino acid residues A500 to A508. The effect of T504 phosphorylation is unclear. This is the major in vivo phosphorylation site in DTNA (≥30 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus).

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 0.65 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Dog | Rat | Mouse | Platypus | Frog.

Scientific Background: DTNA (Dystrobrevin alpha) is a critical, multifunctional component of the dystrophin-glycoprotein complex (DGC) and belongs to the dystrophin family, Dystrobrevin subfamily. It contains an N-terminal EF-hand region, a ZZ domain, and a C-terminal region with potential tyrosine phosphorylation sites, which are homologous to the C-terminus of dystrophin. It is implicated in the formation and stability of synapses as well as being involved in the clustering of nicotinic acetylcholine receptors, by anchoring them at the postsynaptic membrane. It links the DGC to the intracellular cytoskeleton, specifically interacting with proteins like dystrophin, utrophin, sarcoglycans, and intermediate filaments (syncoilin, beta-synemin). It protects cardiomyocytes from membrane damage during stress. It acts as a scaffold for signaling proteins, notably anchoring neuronal nitric oxide synthase (nNOS) to the membrane. The latger 87 kDa isoform, DTNA1, is highly expressed in brain, skeletal and cardiac muscles, and expressed at lower levels in lung, liver and pancreas. Isoform 2 is not expressed in cardiac muscle. Isoform 7 and isoform 8 are only expressed in muscle. Loss of DTNA leads to displacement of nNOS, causing impaired nitric oxide-mediated signaling. Deficiencies in DTNA in mice lead to muscular dystrophy and severe cardiac myopathies due to the failure of both structural and signaling functions. Mutations in DTNA are associated with rare forms of inherited muscular dystrophy, often presenting with high creatine kinase (hyperCKemia) or mild muscle weakness. Mutations in the DTNA gene are associated with congenital heart defects (left ventricular noncompaction; LVNC)), myopathy with myalgia, and elevated serum creatine kinase. This description may include information annotated by UniProt and/or Google AI.